XML 16 R5.htm IDEA: XBRL DOCUMENT v3.19.2
STATEMENT OF STOCKHOLDERS' DEFICIT - 3 months ended May 31, 2019 - USD ($)
Common Stock
Additional Paid-in Capital
Retained Deficit
Total
Balance at Feb. 28, 2019 $ 131,449 $ 121,705,250 $ (122,023,347) $ (186,648)
Balance (in shares) at Feb. 28, 2019 131,448,444      
Increase (Decrease) in Stockholders' Equity        
Cash contributed by S.R. Burzynski, M.D., Ph.D.   138,217   138,217
FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D   316,719   316,719
Net loss     (468,314) (468,314)
Balance at May. 31, 2019 $ 131,449 $ 122,160,186 $ (122,491,661) $ (200,026)
Balance (in shares) at May. 31, 2019 131,448,444